Novel approach could limit common complications of immunotherapy – Medical Xpress
|
Novel approach could limit common complications of immunotherapy
Medical Xpress By connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab) and anti-PD-L1 (atezolizumab) to peptides that bind to tissues in and around tumors, a research team based at the University of Chicago found a way to improve the … |
